| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 549218000 | Phosphorus attached indirectly to the hetero ring by nonionic bonding | 20 |
| 20100152465 | Functionalized Ionic Liquids, and Methods of Use Thereof - One aspect of the present invention relates to ionic liquids comprising a pendant Bronsted-acidic group, e.g., a sulfonic acid group. Another aspect of the present invention relates to the use of an ionic liquid comprising a pendant Bronsted-acidic group to catalyze a Bronsted-acid-catalyzed chemical reaction. A third aspect of the present invention relates to ionic liquids comprising a pendant nucleophilic group, e.g., an amine. Still another aspect of the present invention relates to the use of an ionic liquid comprising a pendant nucleophilic group to catalyze a nucleophile-assisted chemical reaction. A fifth aspect of the present invention relates to the use of an ionic liquid comprising a pendant nucleophilic group to remove a gaseous impurity, e.g., carbon dioxide, from a gas, e.g., sour natural gas. | 06-17-2010 |
| 549220000 | Polycyclo ring system having the hetero ring as one of the cyclos | 11 |
| 20080319209 | Process for Preparing (Disubstitutedpropenyl) Phenylalkyl Substituted Dihydrobenzofurans - An improved process is described for preparing (disubstitutedpropenyl) phenylalkyl substituted dihydrobenzofurans. This improved process is focused on steps to produce key intermediates, namely disubstitutedphenolylalkyl substituted dihydrobenzofurans of formula I: | 12-25-2008 |
| 20090131686 | Sesamol Derivatives or Their Salts, The Process for Preparing the Same, and the Skin External Composition Containing the Same - The present invention relates to a sesamol derivative or its salt, and a skin external composition containing the same. More particularly, the invention relates to a sesamol derivative or its salt, which consists of sesamol and 3-aminopropane phosphoric acid, linked with each other by a phosphoric acid diester bond, and can be degraded into sesamol and 3-aminopropane phosphoric acid by enzymes present on the skin so as to simultaneously show the physiological activities of sesamol and 3-aminopropane phosphoric acid, as well as a preparation method thereof and a skin external composition containing the same. | 05-21-2009 |
| 20110040108 | INOSITOLPHOSPHOLIPIDS AND ANALOGUES PHOSPHATIDYLINOSITOL PRODUCTS AND PROCESSES - Embodiments of the invention relate to natural and synthetic inositolphospholipid (IPL) materials, their preparation and applications. They provide compositions of the parent IPL comprising phosphatidylinositol (PI), PI-phosphates (phosphoinositides) and derivatives and analogues, and a process for their production starting from natural IPL. The embodiments further provide functional derivatives of PI for biomedical applications including a platform for drug design and delivery to therapeutic targets in the phosphoinositide mediated cellular signaling and allied cascades. The embodiments pertain to IPL having absolute stereo-structure. The embodiments further pertain to unique IPL and PI product compositions for defined applications, particularly pharmaceutical compositions for prophylaxis and treatment of diseases related to aberrant cellular and nuclear signaling mediated by PI and PI derived phosphates, and associated phosphoinositide specific enzymes including PI-PLC and PI 3-kinase. | 02-17-2011 |
| 20110218345 | AXIALLY ASYMMETRIC PHOSPHORUS COMPOUND AND PRODUCTION METHOD THEREOF - [Problem to be Solved] To provide an axially asymmetric optically active biarylphosphorus compound that can easily produced without the step of optical resolution which was almost indispensable in conventional methods. | 09-08-2011 |
| 20120046475 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELEOMERIZATION OF BUTADIENE - A phosphine ligand suitable for use in telomerizing butadiene comprises two phenyl groups and a xanthene moiety. | 02-23-2012 |
| 20130018195 | FLUORESCENT CELL MARKERS - The preparation and use of fluorescent cell markers of the structure F—S | 01-17-2013 |
| 20130211102 | CHEMICAL PROCESSES FOR THE MANUFACTURE OF SUBSTITUTED BENZOFURANS - The present invention relates to the scaled-up synthesis of biologically active compounds which display useful therapeutic activity in treating proliferative disorders. In particular the invention relates to process methods for the kilogram scale synthesis of a particular class of substituted benzofuran tubulin polymerisation inhibitors. | 08-15-2013 |
| 20130267714 | BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS - Compounds of the formula (I) in the form of a mixture of predominantly one diastereomer or in the form of pure diastereomers, | 10-10-2013 |
| 20140213800 | DEVICE AND METHOD FOR EVALUATING ORGANIC MATERIAL FOR ORGANIC SOLAR CELL - Provided are a novel 1,2-bis(dialkylphosphino)-4,5-(methylenedioxy)benzene derivative that forms a metal complex having particularly high asymmetry induction capacity and catalytic activity on β-dehydroamino acids, a method for manufacturing the same, a metal complex having this 1,2-bis(dialkylphosphino)-4,5-(methylenedioxy)benzene derivative as a ligand, and an asymmetric hydrogenation method using this metal complex. A 1,2-bis(dialkylphosphino)-4,5-(methylenedioxy)benzene derivative represented by general formula (1). (In the formula, R | 07-31-2014 |
| 20140296539 | Compound and Asymmetric Synthesis Reaction - A compound represented by the following General Formula (1): | 10-02-2014 |
| 20150018566 | TUBULIN BINDING AGENTS - The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature. | 01-15-2015 |
| 549221000 | Plural ring oxygens in the hetero ring | 1 |
| 20140323743 | POLYMETHACRYLIC ACID ANHYDRIDE TELOMERS - The present invention provides hypophosphite (co)telomers of methacrylic anhydride having a weight average molecular weight of from 1,000 to 20,000, and having, on average, at least one phosphorus atom bound to two carbon atoms, and at least one carboxylic acid or salt group. | 10-30-2014 |
| 549222000 | Chalcogen bonded directly to the hetero ring | 7 |
| 20080227991 | Sodium salt of disaccharide compound, production method and use of same - The present invention relates to a sodium salt represented by average formula (I): | 09-18-2008 |
| 20120220786 | PROCESS FOR THE PREPARATION OF FOSAMPRENAVIR CALCIUM - The present invention relates to process for the preparation of fosamprenavir calcium. | 08-30-2012 |
| 20130225839 | PREPARATION METHOD OF FOSAMPRENAVIR DERIVATIVES AND RELEVANT INTERMEDIATE THEREOF - Preparation method of fosamprenavir derivatives is disclosed. The compound shown by formula II or its ammonium salt is reacted with a metal ion source in solvent to obtain the compound shown by formula Iii. After isolating and purifying, the compound shown by formula III is catalytically reduced to the compound shown by formula I. In the formula, X is metal ion. Preferably, the metal ion source is a calcium ion source, sodium ion source, or potassium ion source, and X is calcium ion, sodium ion, or potassium ion. The solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, or sec-butanol. The catalytic reduction is carried out by using hydrogen as a reducing agent in the presence of palladium on carbon catalyst. The ammonium salt is methylamine salt, dimethylamine salt, ethylamine salt, diethylamine salt, isopropylamine salt, dibutylamine salt, dipropylamine salt, t-butylamine salt, or dicyclohexylamine salt. The relevant intermediate of fosamprenavir derivatives in the preparation method is also provided. The preparation method of fosamprenavir derivatives reduces the cost, improves the productivity, and is applicable for large-scale popularization and application. | 08-29-2013 |
| 20130317236 | CRYSTALLINE FOSAMPRENAVIR CALCIUM AND PROCESS FOR THE PREPARATION THEREOF - The main object of the present invention relates to novel crystalline form of Fosamprenavir Calcium designated as Form A. Another object of the present invention relates to a process for the preparation of Crystalline Form A of Fosamprenavir Calcium. Yet another object of the present invention relates to crystalline Form A of Fosamprenavir Calcium characterized by an PXRD diffraction having reflections at about 3.1±0.2, 4.4±0.2, 5.0±0.2, 6.3±0.2, 7.4±0.2, 8.0±0.2, 28. | 11-28-2013 |
| 20140256959 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES - The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparation thereof. The present invention also provides fosamprenavir calcium intermediate, (S)-3-tetrahydrofuranyl-N-succinimidyl carbonate (IIa) substantially free of (R)-3-tetrahydrofuranylsuccinimidyl carbonate (IIb) and its process for preparation thereof. | 09-11-2014 |
| 20150361119 | COMPOUND HAVING LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION MODULATION ACTIVITY - The object of the present invention is to provide a compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof. | 12-17-2015 |
| 20160075643 | NOVEL PROCESS TO PREPARE INTERMEDIATES OF HIV-PROTEASE INHIBITORS THEREOF - The present invention relates to an industrially feasible and economically viable process for the preparation of (1S,2R)-3-[[4-aminophenyl)-sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenyl-methyl)propyl]amine of formula I and its salt thereof and optionally converting it to HIV-protease inhibitors like Darunavir, Amprenavir or its prodrug Fosamprenavir. | 03-17-2016 |
